Walvax

#Walvax aims to become a high-quality, cost-effective and sustainable global #vaccine producer, to help everyone live a healthy life!

[Walvax @WalvaxBiotech]

BREAKING: China's first mRNA vaccine has been officially approved by NMPA.

Developed by Walvax and its partners, this marks a significant breakthrough — and critically, the underlying mRNA platform technology has now been fully validated . #mRNA #Covid #Vaccines #Biotech

[Walvax @WalvaxBiotech]

Great news! Walvax's bivalent HPV vaccine (WALRINVAX®), in partnership with Africare Biopharma, has received Tanzania Medicines and Medical Devices Authority (TMDA) approval for its vial presentation.

A big step in bringing affordable, quality HPV vaccine to Africa!🌍

[Walvax @WalvaxBiotech]

🌍Breaking into West Asia! Walvax's PCV13 vaccine — China's 1st homegrown 13-valent pneumococcal conjugate vaccine — has completed its first commercial delivery to Jordan, making it the first Chinese vaccine officially marketed in the country. 💉
#Vaccines #GlobalHealth #PCV13

[Walvax @WalvaxBiotech]

This #WorldImmunizationWeek, @WHO urges global action on HPV vaccination to eliminate cervical cancer.

Walvax’s HPV2 achieved #WHOPQ in Aug 2024 — meeting international standards for safety, efficacy & quality.

Let’s protect every generation. #VaccinesWork #HPVvaccine

[World Health Organization (WHO) @WHO]

“I don’t want my child to suffer from a disease that can be prevented.”
-Lyudmila, Republic of Moldova

Your decision makes a difference. Get vaccinated https://t.co/aQjPez4LVt

#VaccinesWork
#WorldImmunizationWeek

[Walvax @WalvaxBiotech]

Milestone achieved! Walvax's PPSV23 has begun delivery to the Philippine Department of Health for its EPI. This marks the vaccine's first-ever inclusion as a national immunization program product. With 14M+ doses delivered globally, Walvax continues expanding its global footprint

[Walvax @WalvaxBiotech]

Walvax will be at #ExpoFarma2026 — Latin America's most influential pharma expo!

📅 April 15–17 | 📍 WTC Ciudad de México | 🏷️ Booth #1500

Endless opportunities for collaboration & innovation. Come find us and let's shape the future of vaccine! #Biotechnology #Pharma #Vaccine

[Walvax @WalvaxBiotech]

From the high-level "Vaccine Localization" forum in Cairo: Walvax's PCV13 (Weuphoria) is now launched in Egypt!

A landmark moment for pediatric care in Egypt, combining disease protection with strategic local manufacturing goals.

#VaccineLocalization #Cairo #PCV13

[Walvax @WalvaxBiotech]

Walvax shines at #CPHI Europe 2025! 🌍
Productive meetings with partners from 20+ countries and promising discussions with new collaborators. Our vaccines now reach 25 countries globally with 30+ registration projects in progress.

#CPHIFrankfurt #GlobalHealth #Vaccines

[Walvax @WalvaxBiotech]

We're excited to announce Walvax will be exhibiting at CPHI Frankfurt 2025!
📅 October 28-30, 2025
📍 Messe Frankfurt, Germany
🏢 Visit us at Stand 4.1B48
We look forward to welcoming partners and friends. Stop by to connect and explore opportunities together!
#CPHIFrankfurt

[Walvax @WalvaxBiotech]

🎉Exciting news! Walvax's PCV13 vaccine has received regulatory approval from Jordan's FDA - marking the 9th registration certificate for this product. This achievement demonstrates growing international recognition and confidence in the vaccine's safety and efficacy.#Walvax #PCV

[Glocal @sfc_glocal]

沃森生物的全球化征程与香港机遇
@WalvaxBiotech
https://t.co/H9L78eKczV

[Walvax @WalvaxBiotech]

Great turnout at our Walvax booth during Pharmaist Exhibition! Thank you to all the guests and visitors who stopped by to learn about our latest innovations. Exciting conversations and valuable connections made. #Walvax #Pharmaist #Vaccines #Innovation

[Walvax @WalvaxBiotech]

🇹🇷 Excited to announce that Walvax will be exhibiting at #Pharmaist2025 in Istanbul!
📅 June 18-20, 2025
📍Istanbul Expo Center
🤝Booth A133, Hall 1
We look forward to welcoming visitors and connecting with you!

#Pharmaist #Istanbul #Healthcare #Innovation #Walvax #vaccines

[Walvax @WalvaxBiotech]

Walvax released its 2024 Annual Report and ESG Report. Revenue reached $387M USD with $78M coming from international markets, representing a 98% year-on-year growth. 🥳Read 2024AR at https://t.co/9U5UBF57WQ and 2024 ESG Report at https://t.co/jrBoyX4R5Q #Walvax #AnnualResults

[Walvax @WalvaxBiotech]

Exciting news! 🌐Walvax's novel pneumococcal conjugate vaccine technology selected as one of the "100 Best Industrial Innovative Technologies for International Cooperation" at the 2025 International Technology Trade Fair on ZGC Forum #Innovation #HealthTech

[Walvax @WalvaxBiotech]

Excited to announce that Walvax is at #VIFWorld2025 in Shanghai! We're presenting critical safety data from our Phase IV clinical trial on single-dose PPSV23 vaccine. Proud to contribute to this year's theme of "Bridging Science and Society." #VaccineInnovation #Walvax

[Walvax @WalvaxBiotech]

As we welcome 2025, Walvax extends heartfelt gratitude to our valued partners. Your trust and collaboration continue to help everyone live a healthy life. Wishing you prosperity, good health, and success in the year ahead. #NewYear2025 #Healthcare #Walvax #Vaccines

[Walvax @WalvaxBiotech]

Join us at CPHI Middle East 2024! Visit Walvax at Booth 3.A22 in the Bioproduction Pavilion, Riyadh Front Exhibition Center, Saudi Arabia, Dec 10-12. We look forward to meeting you and discussing innovative solutions! #CPHIMiddleEast2024 #BioPharma #SaudiArabia

[Walvax @WalvaxBiotech]

#WorldPneumoniaDay Pneumonia remains a leading cause of child mortality, but it's preventable. Pneumococcal vaccines save lives - ensuring your child gets the PCV vaccine is crucial for their protection. Walvax's PCV13 protects against 13 pneumococcal strains. #StopPneumonia 🫁💉

[United Nations @UN]

Pneumonia kills more than 700,000 children every year, accounting for nearly 15% of all deaths of children under 5.

On Tuesday’s #WorldPneumoniaDay, see how @WHO is working to protect, prevent & treat pneumonia in children. https://t.co/3rPsuHjKgc

[Walvax @WalvaxBiotech]

Walvax Biotechnology's #ESG rating upgraded to BBB by @MSCI_Inc in 2024. Notably, Access to Health Care and Product Safety & Quality score above industry average.👏 #SustainableInvesting #Biotech #Healthcare #ESGratings